To explore the underlying mechanism, we reanalyzed breast cancer data from The Cancer Genome Atlas, which revealed that LOX expression correlates with expression of matrix metallopeptidase 2 (MMP2) (Figure 3A, R2 = 0.47), collagen type I alpha1 (COL1A1) (Figure 3B, R2 = 0.47), and secreted protein acidic and rich in cysteine (SPARC) (Figure 3C, R2 = 0.51). Here, LOX is linked to breast carcinoma.